{"name":"Stealth BioTherapeutics Inc.","slug":"stealth-biotherapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Bendavia","genericName":"Bendavia","slug":"bendavia","indication":"Other","status":"discontinued"}]}],"pipeline":[{"name":"Bendavia","genericName":"Bendavia","slug":"bendavia","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxNamdqdkVNNFpJUmJwT1JYbUY1bmx6WFZsNzhUTjJzdDg0dWRDcW9OaDZkaldBZ0JJeEFhQVd0bjJFMU9MUm5GQl94ZlhtcVp4SnNnVjZwLUNXQVlSdnpRd3NLMFV3eVB2Ym5TeVo0NzBjb29heF9kdk44ejU1NFNRUnBsN0N3OXFkUWdQeWNrUTR3a01VenJTVUlQV0JXYlo1RWQyT1BRNDlfekplcTJaLThZRFI4VFBNdldEVEJETUU0cVpiODJNbXlkMXZzWWhySTNsSVp2YktOMGxIVFFyQ3c2X19jLS14YXBQc2o1NWNmcFU?oc=5","date":"2026-01-06","type":"pipeline","source":"prnewswire.com","summary":"Stealth BioTherapeutics Provides Commercial and R&D Pipeline Update and Outlines 2026 Strategic Priorities - prnewswire.com","headline":"Stealth BioTherapeutics Provides Commercial and R&D Pipeline Update and Outlines 2026 Strategic Priorities","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywJBVV95cUxNal9yb0poS19QYmQ1U3N3bGFzYXJ3VVFoNFZ1bFBEbWFTRGIwbmZOcVdqR0JaSWtsNjR1dVhjNzRaVFJLUzJBSDQtRUpha1VkNW9WSDdlY3pOd2FHeTRHXzhtUEZwMlJYSWFoWUhucWQ1eWdtTEkxNzR1MHlrSGpvUnBkZVE0ODlWQVpoRWhBS19iSUlXY3FsemVFd0xzV2RmOV91MUxSZ2NoWTFnNjFqQXF1QW83YzRTNDZlZ0FNYmZha1dGRjVNbzViMldQSXdyRXl6V1EtVmdRYlZOZHZuTnVQU2ZZR1NZQ0hqRmpuZkw1X09uRHMzd0duNlpOZlhULWMzRnVlajBBb3g0OWJYQnExeGNMc2ZqZHFuMld5YmFObkVMZFF0VXJLT3BpRVRFM3ZUS2Q4TGw4TDhLUUhGS1V4VU1kbS00Q0NR?oc=5","date":"2025-12-01","type":"pipeline","source":"GlobeNewswire","summary":"Geographic Atrophy Market to Surge Significantly During the - GlobeNewswire","headline":"Geographic Atrophy Market to Surge Significantly During the","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwJBVV95cUxQdjA4NjRPMVVoaVhDdmI1M2tpb0pyWlNpd3hTLVRNT01zNXVJc3NPQUpnUUEyV1pqZWNUN2lXdFdDX3dkcUNuTklNWU9NMzNQWGFXcGtRNF94QW5BTkhnYTBqN25OTmpBUVB4YXZTalg5UnN3TkNKZTdqa0ZyM2Njc21EX1MtQ0F6Y19pVHlNeXM0R21OV3dKaU01aHNOSzRBcV9CWWlmNFlHS25hQ3R5S1VKRjQyRmZWOWE2UHNRclJEakY4X1ZLekEtNmViMkFpclRzaldDT1RVaHBoanhNbUJBVG41NUxtTE1XUGxfa3JaZXQwUW54enQ1cFN3NmtwUTJHUlR0c0tHWHRLTDFKSlNuSnlEaUNRa2JqYXk5aGZKQTdOaTk0YTVyUnpKaHRiNDQwNmJkUFFJS2dhckhpN3BxNVkzRjg?oc=5","date":"2025-11-17","type":"pipeline","source":"GlobeNewswire","summary":"Dry Age-related Macular Degeneration Market Poised for - GlobeNewswire","headline":"Dry Age-related Macular Degeneration Market Poised for","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPemtHRW1ybGxDR1R3TmZRd0xmZkgyTVJNZ09lLXhSMHRLZ2c1NEk3c2s1b2U4RXA1TEl6M2xaYUM4ZDVmNkN4THlfdW5FVHY5d0ROVVdGYlgxdmJRVnNwWXhiNDNoWkJLVVdEZnN0N2dzUGk4UkYtWElMWGY2cmJuamdwZWVpb2h5WG5lSHRnbzVuSFdveWc?oc=5","date":"2025-10-09","type":"deal","source":"Yahoo Finance","summary":"Stealth BioTherapeutics Announces Mito Assist™ Patient Support Program and Specialty Pharmacy Partnership with AnovoRx to Distribute FORZINITY™(elamipretide) injection - Yahoo Finance","headline":"Stealth BioTherapeutics Announces Mito Assist™ Patient Support Program and Specialty Pharmacy Partnership with AnovoRx t","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPRjhZcm5vQXNSaW5tckxxS3JxTnRQLTRaWjZuQlZOZ3R2RkVYdGlqOUpzYVV1alRwc2VkdjJNU0w5R0hGVUdIZlhYaVBSTF94OXpwV0xrVExDSllKRWVDZUJ1OUd3aGx5aDFkVEY2U24wRlhBRUhvRVJTcEJWX2F6dko4UUNFZFNQTnVVT3gzRWg3ZVd4NDJPQUhwWXBBV25POWZnYjA4QV9fTmhNaHE0NWpQMnFUbmla?oc=5","date":"2025-09-22","type":"regulatory","source":"BioPharma Dive","summary":"FDA clears first Barth syndrome drug amid scrutiny of rare disease stance - BioPharma Dive","headline":"FDA clears first Barth syndrome drug amid scrutiny of rare disease stance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gJBVV95cUxQcTQwS3NTQW5NSzlDZWlpWkVKWG51YU5IOUxUNGhFakxLNE00bm85VmUtTzI4U1g4ZzdtaGl6T013d29QeEgteFAwQkNhdG9KT1FwVlpqM3BqTXpicS1OM0ljUDhyZU9xM0V3aWdkVjlxZDRpNUtON1p3bWQ2QnA5MkpoaC1jN0VRMUU4VWF2OUJSUlJmMDV6eHVtbTBzaFMxRTAwYm1wLXh6QkVDSGRmczQ1M01wNFB3dW5TeC1GNDhMaUpiRGpCME5JNnZNNU11eEJ4T3ktQmNHaGxmT1lYcThfVDctZWpHSU8xSGE0amo2TEhDRFQ0N0hEdlBGNC1aVHlkUHYzYlV3UndicmJhcUpxLVpVOHRyVm9EeUJaczNONTJibFQ1NXZWOTF5TVlEeU4ycTNhbnV6Slk3ajdKUWNNU3pUZnlFWWVSLXJEc2lmclhPS3ZSa1RR?oc=5","date":"2025-09-19","type":"regulatory","source":"prnewswire.com","summary":"Stealth BioTherapeutics Announces FDA Accelerated Approval of FORZINITY™ (elamipretide HCl), the First Therapy for Progressive and Life-limiting Ultra-rare Genetic Disease Barth Syndrome - prnewswire.","headline":"Stealth BioTherapeutics Announces FDA Accelerated Approval of FORZINITY™ (elamipretide HCl), the First Therapy for Progr","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxQbXJGOVVnNjRiT29mTTRobWFIM3NfVF8wbjZlalFUUzhvVzhjR2FwUklFYjJCa0pwTzJYSEZDVThlUVdGbXhCLTA3R2V4aXFvSVBhUFk3dHpTZ1lHSG5xeV80NnFyM3J6a0ptQ3B6ZEp0M19FanIyMFhEaFhWZ0RJcEM5X0NkN3czZFE4R1dKQU5laWdIcHFnaXUtQVNJdkdzRzBqcWhmQmg5WXgzUW52TThOWFdZWlN4Y1BzT1dZVTRXZUFscDdWQVZBa1JIT29CZEww?oc=5","date":"2025-08-21","type":"regulatory","source":"prnewswire.com","summary":"STEALTH BIOTHERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF ELAMIPRETIDE NDA RESUBMISSION - prnewswire.com","headline":"STEALTH BIOTHERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF ELAMIPRETIDE NDA RESUBMISSION","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPNnN5SE0yeE5kaTB2Sk1hVEdGaVREMjVEME56M3dNQkhkdXM5UjZ6SGFteUFVZjdVaG5wbUdYM0dmdzJIWFJJdGE3b2Z3VW5rX3pmaFAtSm5ua2I3MzhJQ19kYkxnUGpSaWUwODJCdHc5anFFRUxsN2ZINGhDVkZMRGdLLWxGcnpSbVhkZmdqei1HMkZUWHhrUmNYUXNxN3VWRS0zUW5CeTJVUTJYdEZfX1c0QmRaYUxIOGc?oc=5","date":"2025-08-08","type":"regulatory","source":"Fierce Biotech","summary":"Stealth Bio questions its own viability as FDA directs rare disease biotech to resubmit drug application - Fierce Biotech","headline":"Stealth Bio questions its own viability as FDA directs rare disease biotech to resubmit drug application","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOV180dmE0OVhjUTNHTUhndjBBWWNpQi1sblFpa2dicXVWZnFSaHhMQ09BcWJ5ejJiVHFIVEJoUXdvNnlrZXBMZC16TkozbFhDaVRRMWt2SFRlVUtkTHpVSnIzSS1OcGtOVFJwNzdELXR5OW0tY1FoVkxER0d6TGk2Q0IwcHZjMVQzVUFpZXl3?oc=5","date":"2025-05-30","type":"regulatory","source":"pharmaphorum","summary":"Axe falls on Stealth Bio staff after FDA rejects lead drug - pharmaphorum","headline":"Axe falls on Stealth Bio staff after FDA rejects lead drug","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxNQWhSb2N6U09aX1pvdFh2azM0cHc1MXRCWVZPcF8tQXdlblJwUFh5bVJKNkZwS0lCSXRGbDhIQkc5QWZiMnVSN2phaVVSX0g1QVFMVzZCNE9aQWNOSHJPb1ppd0ZhRWRRYzd1cGUwVE0zWVYwaFF2NUF2NUMxb090MXllYWR4MTdKSHNXSzlTdWViTGxIbG9nNUNUbjVvcWlCQjF2TTd4U3hPbWlMVFJSRDVWYVdLYmM5VEJEajF6dHZaVmhxTldYU0FJUnFCQ29MbHVMamtFS2cxOG5TQ1Q3Wkh6QVZvUQ?oc=5","date":"2025-05-29","type":"regulatory","source":"Reuters","summary":"Stealth Bio to cut jobs after FDA rejects therapy for rare disorder - Reuters","headline":"Stealth Bio to cut jobs after FDA rejects therapy for rare disorder","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxQSmVocXFyZmZwTnNHcHZYYTNtMzNEcXVyV1U1T19TcmZiVEZkMk8xRVRXZGRTWXM5MWVKd3Y0VG9rWV9mZW1FdkIxMXoxRGctNEFLOHpEdGQ2TW0wSHo0N0JXZk93U3FKNFRTdV9fWVJYUklwWEplc3JaanRhRXpNcG5CcW5FWk9TeFFzZ2NxYS03LXhsd0ItX0hBVnNzczhFQXpuRGd6ZEhBTzZGZFlnaWxRSzFmdXpnNUgxODA5Q1VROWRCUDhuRzVabV9udXdPQjVrbDRGM0dVb2w3aDJNNExsNkVKX21UaEZqR1dCVnN3dw?oc=5","date":"2025-05-29","type":"pipeline","source":"prnewswire.com","summary":"Stealth BioTherapeutics Announces \"Path Forward\" Despite Disappointing Delay for Ultra-rare Barth Syndrome - prnewswire.com","headline":"Stealth BioTherapeutics Announces \"Path Forward\" Despite Disappointing Delay for Ultra-rare Barth Syndrome","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxNVFVJTFk2WEU1U2EwT2ExRmk2eGl5SjMyLWdZcWlGcThyV2ZMeWJRa2FfUHYybWZ5R0NqWE8xbmVXZEZhVVFLMUlyc0o5ZmRNZ3RQN2cwYVZUd1MzRF80MWdRU0x6ZlhUVnBoSFhCWXViMkhBMXVJY0praVVIanpKR0FUdnA1R0Ytb0RGeVIySUFDN1luNlFzQUYwM3FWS2JweThta0Q0UzliUW13WnNER09uem91WjZZUFRHVjFBNG1OY0o4aDlGSmdrV204eFM4TWxYMWZWNEdac1hGeHlB?oc=5","date":"2025-04-29","type":"regulatory","source":"prnewswire.com","summary":"Stealth BioTherapeutics Announces Delay in FDA Action Date for Barth Syndrome Application - prnewswire.com","headline":"Stealth BioTherapeutics Announces Delay in FDA Action Date for Barth Syndrome Application","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"discontinued":1},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}